Status:
TERMINATED
Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
Intergroupe Francophone du Myelome
URC-CIC Paris Descartes Necker Cochin
Conditions:
Multiple Myeloma
Eligibility:
All Genders
65-75 years
Brief Summary
The aim of this study is looking at the Kinetics of bone turnover markers (C-terminal telopeptides of type I collagene (CTX), amino-terminal telopeptide of type 1 collagen (NTX), Dickkopf-1 (DKK-1) an...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patient aged 65 to 75 years of age
- Patient with symptomatic multiple myeloma as defined by the criteria of the IMWG
- Need to introduced an antiresorptive bone treatment by intravenous bisphosphonate with bone imaging mapping (PET-scanner preferentially) in routine care
- Ability and willingness to follow scheduled visits with requested biological samples
- Exclusion Criteria
- \- Patients previously treated with intravenous biphosphonate
Exclusion
Key Trial Info
Start Date :
September 29 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 20 2020
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT04111809
Start Date
September 29 2020
End Date
October 20 2020
Last Update
September 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Necker Hospital, Adult haematology department
Paris, France, 75015